The proton-coupled folate transporter: Impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier

Molecular Pharmacology

Volumn 74, Issue 3, 2008, Pages 854-862

  Zhao, Rongbao ^a   Qiu, Andong ^a   Tsai, Eugenia ^a   Jansen, Michaela ^a   Akabas, Myles H ^a   Goldman, I David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; FOLATE RECEPTOR; FOLINIC ACID; METHOTREXATE; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; PEMETREXED; PROTON COUPLED FOLATE TRANSPORTER PROTEIN; RALTITREXED; REDUCED FOLATE CARRIER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL GROWTH; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG TRANSPORT; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOAD;

ANIMALS; BIOLOGICAL TRANSPORT; CELL PROLIFERATION; CLONE CELLS; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; INTRACELLULAR SPACE; KINETICS; MEMBRANE TRANSPORT PROTEINS; PROTONS; TRANSFECTION; TRITIUM; XENOPUS;

EID: 50549085728     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.045443     Document Type: Article

References (33)

1. Andreassi JL 2nd and Moran RG (2002) Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry 41:226-235.
2. Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, and Goldman ID (2007) Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12:808-815.
3. Chattopadhyay S, Zhao R, Krupenko SA, Krupenko N, and Goldman ID (2006) The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 5:438-449.
4. Goldman ID, Min SH, Sandoval C, and Kronn D (2008) Heriditary folate malabsorption. Gene Reviews. Available at http://www.ncbi.nlm.nih.gov/ bookshelf/br.Fcgi?book=gene&part=folate-mal.
5. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, and Bertino JR (1997) Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89:1013-1018.
6. Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, and Gorlick R (1999) Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 5:621-627.
7. Helmlinger G, Yuan F, Dellian M, and Jain RK (1997) Interstitial PH and PO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3:177-182.
8. Henderson GB and Strauss BP (1990) Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells. Cancer Res 50:1709-1714.
9. Henderson GB and Zevely EM (1983) Use of non-physiological buffer systems in the analysis of methotrexate transport in L1210 cells. Biochem Int 6:507-515.
10. Kamen BA and Smith AK (2004) A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 56:1085-1097.
11. Kamen BA, Smith AK, and Anderson RGW (1991) The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. J Clin Invest 87:1442-1449.
12. Matherly LH and Goldman DI (2003) Membrane transport of folates. Vitam Horm 66:403-456.
13. Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, Buck S, Wright JE, and Rosowsky A (1995) Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85:500-509.
14. Piedrahita JA, Oetama B, Bennett GD, van Waes J, Kamen BA, Richardson J, Lacey SW, Anderson RG, and Finnell RH (1999) Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet 23:228-232.
15. Prasad PD, Mahesh VB, Leibach FH, and Ganapathy V (1994) Functional coupling between a bafilomycin A1-sensitive proton pump and a probenecid-sensitive folate transporter in human placental choriocarcinoma cells. Biochim Biophys Acta 1222:309-314.
16. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, and Goldman ID (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127:917-928.
17. Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, Matherly LH, Zhao R, Akabas MH, and Goldman ID (2007) Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol 293:C1669-C1678.
18. Salazar MD and Ratnam M (2007) The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26:141-152.
19. Sharif KA and Goldman ID (2000) Rapid determination of membrane transport parameters in adherent cells. BioTechniques 28:926-928, 930, 932.
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
21. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM, et al. (1995) Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48:459-471.
22. Wike-Hooley JL, Haveman J, and Reinhold HS (1984) The relevance of tumour PH to the treatment of malignant disease. Radiother Oncol 2:343-366.
23. Wollack JB, Makori B, Ahlawat S, Koneru R, Picinich SC, Smith A, Goldman ID, Qiu A, Cole PD, Glod J, et al. (2008) Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem 104:1494-1503.
24. Wong SC, Zhang L, Proefke SA, and Matherly LH (1998) Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier. Biochim Biophys Acta 1375:6-12.
25. Yang CH, Dembo M, and Sirotnak FM (1983) Relationships between carrier-mediated transport of folate compounds by L1210 leukemia cells: evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles. J Membr Biol 75:11-20.
26. Zhao R, Babani S, Gao F, Liu L, and Goldman ID (2000) The mechanism of transport of the multitargeted antifolate, MTA-LY231514, and its cross resistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 6:3687-3695.
27. Zhao R, Chattopadhyay S, Hanscom M, and Goldman ID (2004a) Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Clin Cancer Res 10:8735-8742.
28. Zhao R, Gao F, Hanscom M, and Goldman ID (2004b) A prominent low-pH methotrexate transport activity in human solid tumor cells: contribution to the preservation of methotrexate pharmacological activity in HeLa Cells lacking the reduced folate carrier. Clin Cancer Res 10:718-727.
29. Zhao R and Goldman ID (2003) Resistance to antifolates. Oncogene 22:7431-7457.
30. Zhao R and Goldman ID (2007) The molecular identity and characterization of a proton-coupled folate transporter-PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev 26:129-139.
31. Zhao R, Hanscom M, Chattopadhyay S, and Goldman ID (2004c) Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier; association with the presence of a secondary transport pathway. Cancer Res 64:3313-3319.
32. Zhao R, Min SH, Qiu A, Sakaris A, Goldberg GL, Sandoval C, Malatack JJ, Rosenblatt DS, and Goldman ID (2007) The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption. Blood 110:1147-1152.
33. Zhao R, Russell RG, Wang Y, Liu L, Gao F, Kneitz B, Edelmann W, and Goldman ID (2001) Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 276:10224-10228.